235 related articles for article (PubMed ID: 20059643)
21. The role of disulfide-bridge on the activities of H-shape gemini-like cationic lipid based siRNA delivery.
Ma XF; Sun J; Qiu C; Wu YF; Zheng Y; Yu MZ; Pei XW; Wei L; Niu YJ; Pang WH; Yang ZJ; Wang JC; Zhang Q
J Control Release; 2016 Aug; 235():99-111. PubMed ID: 27242198
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
Zhang P; An K; Duan X; Xu H; Li F; Xu F
Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
[TBL] [Abstract][Full Text] [Related]
23. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
24. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies.
Weinstein S; Toker IA; Emmanuel R; Ramishetti S; Hazan-Halevy I; Rosenblum D; Goldsmith M; Abraham A; Benjamini O; Bairey O; Raanani P; Nagler A; Lieberman J; Peer D
Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E16-22. PubMed ID: 26699502
[TBL] [Abstract][Full Text] [Related]
25. Strategies for in vivo siRNA delivery in cancer.
Sanguino A; Lopez-Berestein G; Sood AK
Mini Rev Med Chem; 2008 Mar; 8(3):248-55. PubMed ID: 18336345
[TBL] [Abstract][Full Text] [Related]
26. Anionic amino acid-derived cationic lipid for siRNA delivery.
Suh MS; Shim G; Lee HY; Han SE; Yu YH; Choi Y; Kim K; Kwon IC; Weon KY; Kim YB; Oh YK
J Control Release; 2009 Dec; 140(3):268-76. PubMed ID: 19567256
[TBL] [Abstract][Full Text] [Related]
27. Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes.
Shim G; Choi HW; Lee S; Choi J; Yu YH; Park DE; Choi Y; Kim CW; Oh YK
Mol Ther; 2013 Apr; 21(4):816-24. PubMed ID: 23380818
[TBL] [Abstract][Full Text] [Related]
28. Liposomal siRNA for ovarian cancer.
Mangala LS; Han HD; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2009; 555():29-42. PubMed ID: 19495686
[TBL] [Abstract][Full Text] [Related]
29. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
[TBL] [Abstract][Full Text] [Related]
30. Proof of concept studies for siRNA delivery by nonionic surfactant vesicles:
Obeid MA; Dufès C; Somani S; Mullen AB; Tate RJ; Ferro VA
J Liposome Res; 2019 Sep; 29(3):229-238. PubMed ID: 30296860
[TBL] [Abstract][Full Text] [Related]
31. Single siRNA nanocapsules for enhanced RNAi delivery.
Yan M; Liang M; Wen J; Liu Y; Lu Y; Chen IS
J Am Chem Soc; 2012 Aug; 134(33):13542-5. PubMed ID: 22866878
[TBL] [Abstract][Full Text] [Related]
32. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro.
Resnier P; David S; Lautram N; Delcroix GJ; Clavreul A; Benoit JP; Passirani C
Int J Pharm; 2013 Oct; 454(2):748-55. PubMed ID: 23583841
[TBL] [Abstract][Full Text] [Related]
33. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery.
Biswas S; Deshpande PP; Navarro G; Dodwadkar NS; Torchilin VP
Biomaterials; 2013 Jan; 34(4):1289-301. PubMed ID: 23137395
[TBL] [Abstract][Full Text] [Related]
34. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
35. Functionalized bioengineered spider silk spheres improve nuclease resistance and activity of oligonucleotide therapeutics providing a strategy for cancer treatment.
Kozlowska AK; Florczak A; Smialek M; Dondajewska E; Mackiewicz A; Kortylewski M; Dams-Kozlowska H
Acta Biomater; 2017 Sep; 59():221-233. PubMed ID: 28694238
[TBL] [Abstract][Full Text] [Related]
36. Sustained small interfering RNA delivery by mesoporous silicon particles.
Tanaka T; Mangala LS; Vivas-Mejia PE; Nieves-Alicea R; Mann AP; Mora E; Han HD; Shahzad MM; Liu X; Bhavane R; Gu J; Fakhoury JR; Chiappini C; Lu C; Matsuo K; Godin B; Stone RL; Nick AM; Lopez-Berestein G; Sood AK; Ferrari M
Cancer Res; 2010 May; 70(9):3687-96. PubMed ID: 20430760
[TBL] [Abstract][Full Text] [Related]
37. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.
Höbel S; Koburger I; John M; Czubayko F; Hadwiger P; Vornlocher HP; Aigner A
J Gene Med; 2010 Mar; 12(3):287-300. PubMed ID: 20052738
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Landen CN; Chavez-Reyes A; Bucana C; Schmandt R; Deavers MT; Lopez-Berestein G; Sood AK
Cancer Res; 2005 Aug; 65(15):6910-8. PubMed ID: 16061675
[TBL] [Abstract][Full Text] [Related]
39. Effects of cationic lipids in cationic liposomes and disaccharides in the freeze-drying of siRNA lipoplexes on gene silencing in cells by reverse transfection.
Hattori Y; Hu S; Onishi H
J Liposome Res; 2020 Sep; 30(3):235-245. PubMed ID: 31185779
[TBL] [Abstract][Full Text] [Related]
40. Polymer-lipid hybrid nanomedicines to deliver siRNA in and against glioblastoma cells.
Rinaldi A; Dumas F; Duskey JT; Imbriano C; Belluti S; Roy C; Ottonelli I; Vandelli MA; Ruozi B; Garcion E; Tosi G; Boury F
Int J Pharm; 2024 Apr; 654():123994. PubMed ID: 38484859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
